RABL3 and pancreatic neoplasm: These proteins consist of the N-terminal portions of RabL3 (Nissim et al., 2019) or Rab22a (Liao et al., 2020), and exhibit enhanced binding to SmgGDS-607 and SmgGDS-558 in pancreatic cancer (Nissim et al., 2019) and osteosarcoma (Liao et al., 2020), respectively, and are also detected in breast cancer (Nissim et al., 2019; Liao et al., 2020).